Impact of Cannabis Use and Abstinence on Emotion (ICAE)
30 juillet 2026 mis à jour par: Rick James Macatee, Florida State University
Impact of Cannabis Withdrawal and Early Abstinence on Threat and Reward Processing
The goal of this experimental study is to test how three weeks of cannabis abstinence impacts threat and reward processing in females with Cannabis Use Disorder. The main questions it aims to answer are:
Compared to using cannabis as usual, will cannabis cue reactivity increase throughout three weeks of abstinence from cannabis?
Compared to using cannabis as usual, will threat reactivity be elevated at weeks 1 and 2 of abstinence followed by a decrease at week 3 of abstinence?
Compared to using cannabis as usual, will non-drug reward reactivity be lower at weeks 1 and 2 of abstinence followed by an increase at week 3 of abstinence?
Compared to successful 3-week abstainers, will threat, non-drug reward, and cannabis cue reactivity differ in relapsers?
Researchers will compare females with CUD who abstain from cannabis for three weeks to those who continue to use cannabis as usual to see how cannabis abstinence impacts threat and reward processing.
Participants will:
Be randomly assigned to continue using cannabis as usual or abstain from cannabis for three weeks Visit the lab 6 times over three weeks, followed by a 1-month follow-up lab visit for the participants assigned to the cannabis abstinence condition Complete phone surveys every other day across the three week study period
Aperçu de l'étude
Statut
Complété
Les conditions
Type d'étude
Interventionnel
Inscription (Réel)
30
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Florida
-
Tallahassee, Florida, États-Unis, 32304
- The BRAINS Lab in the Department of Psychology at Florida State University
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
- >=5 cannabis use days per week on average over the past 3 months
- Female
- >=6 past-year CUD symptoms (must include withdrawal and at least one criterion other than craving must be met within the past 3 months)
- >=20 days of cannabis use over the past 30 days
- Positive urinalysis for THC
- Cannabis is primary substance of abuse
Exclusion Criteria:
- Current pregnancy
- History of psychotic, seizure, or cardiovascular disorder
- Immediate plan to quit cannabis
- Current treatment for cannabis use
- Current daily psychotropic medication use
- Lotion allergy
- Positive urinalysis for any drug other than THC
- CSRSS >= 4
- Current moderate (4+ criteria) or severe (6+ criteria) substance use disorder (SUD) other than CUD or nicotine dependence
- CBD use >= 9 days
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Contingency Management for Cannabis Abstinence and Lab Visit Attendance
Participants randomly assigned to this arm will receive contingency management for three weeks to reinforce sustained abstinence from cannabis and attendance at all lab visits.
|
Escalating monetary reinforcement is provided for continuous cannabis abstinence and lab visit attendance across the three week study period.
|
|
Autre: Contingency Management for Lab Visit Attendance
Participants randomly assigned to this arm will receive contingency management for three weeks to reinforce attendance at all lab visits.
Participants will continue to use cannabis as usual.
|
Escalating monetary reinforcement is provided for lab visit attendance across the three week study period.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Late Positive Potential
Délai: Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
|
The Late Positive Potential (neural measure recorded via electroencephalography) will be quantified from ~400 to 3000ms at central-parietal sensors relative to the onset of a cannabis, neutral, unpleasant, or pleasant image.
The Late Positive Potential to cannabis vs. neutral and cannabis vs. pleasant will be the primary contrasts of interest.
|
Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
|
|
Reward Positivity
Délai: Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
|
The Reward Positivity (neural measure recorded via electroencephalography) will be quantified from ~200-300ms at frontal-central sensors relative to the onset of monetary win and loss feedback.
The win vs. loss contrast will be the primary outcome of interest.
|
Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
|
|
Eyeblink Startle Response
Délai: Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
|
The Eyeblink Startle Response (recorded via EMG sensors) will be quantified as the peak blink amplitude relative to the onset of an auditory startle probe during blocks with predictable shocks, unpredictable shocks, and no threat of shock.
The Eyeblink Startle Response during unpredictable shock threat vs. no shock threat will be the primary contrast of interest.
|
Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Delta Power
Délai: Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
|
Delta Power (neural time-frequency measure recorded via electroencephalography) will be quantified as event-related spectral power from 1-3.5Hz at frontal-central sensors relative to the onset of monetary win and loss feedback.
The win vs. loss contrast will be the primary outcome of interest.
|
Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
|
|
Delta Intertrial Phase Coherence
Délai: Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
|
Delta Intertrial Phase Coherence (neural time-frequency measure recorded via electroencephalography) will be quantified as intertrial phase coherence of 1-3.5Hz oscillations at frontal-central sensors relative to the onset of monetary win and loss feedback.
The win vs. loss contrast will be the primary outcome of interest.
|
Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
24 janvier 2022
Achèvement primaire (Réel)
15 juillet 2024
Achèvement de l'étude (Réel)
15 juillet 2024
Dates d'inscription aux études
Première soumission
30 juillet 2026
Première soumission répondant aux critères de contrôle qualité
30 juillet 2026
Première publication (Réel)
5 août 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
5 août 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
30 juillet 2026
Dernière vérification
1 juillet 2026
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- AUIRB#20-217FB
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .